SOMALOGIC INC

Their core work

SomaLogic is a US-based proteomics technology company that develops and operates the SomaScan platform — an aptamer-based assay capable of measuring thousands of proteins simultaneously from a small blood sample. In EU research consortia, they contribute as a specialist technology provider, supplying large-scale protein measurement services that most academic partners cannot replicate in-house. Their core value is converting biological samples from large multi-center clinical trials into high-dimensional proteomic datasets suitable for biomarker discovery. They have applied this capability to identify protein signatures in cardiovascular disease and metabolic liver conditions.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2017, so SomaLogic's EU engagement is essentially a single cohort rather than a long arc. Within that cohort, the earlier keyword cluster — heart failure, atrial fibrillation, acute coronary syndrome — reflects their initial EU focus on acute cardiovascular events. The later project, LITMUS, running four months longer to 2024, shifted application to NAFLD biomarkers, pointing toward metabolic and chronic liver disease as a growing area of interest. The technology platform is unchanged; what evolved is the organ system and disease category being interrogated with it.

SomaLogic appears to be broadening the therapeutic areas they serve with their proteomics platform, moving beyond cardiology into hepatology — making them a candidate partner for any large-scale EU biomarker program in metabolic, inflammatory, or chronic disease.

How they like to work

SomaLogic has never led an EU project — in both participations they joined as a specialist contributor within large, multi-site clinical consortia. With 76 unique partners from just 2 projects, they clearly operate in complex, well-funded research networks rather than small bilateral collaborations. This pattern suggests they are sought out for their technology assets and integrated into consortia early, providing a measurement service layer that underpins the work of clinical and academic partners.

Despite only two projects, SomaLogic has connected with 76 unique consortium partners across 18 countries — a footprint typical of large EU clinical trial networks in cardiology and hepatology. Their geographic reach is broad rather than regionally concentrated, which reflects the multi-country patient cohort structures common in both BigData Heart and LITMUS.

What sets them apart

SomaLogic is one of very few US-based commercial proteomics companies with active participation in EU H2020 health research, which signals both scientific credibility and regulatory awareness in a European clinical context. Their aptamer-based platform for measuring thousands of proteins in parallel is a genuinely differentiated capability — not something most university or hospital partners can replicate locally. For a consortium building a biomarker discovery or validation program, SomaLogic brings industrial-grade measurement infrastructure and a proprietary protein database that dramatically expands the search space beyond standard immunoassay panels.

Highlights from their portfolio

• BigData Heart
  A major IMI-funded cardiovascular consortium covering three distinct cardiac conditions simultaneously — heart failure, atrial fibrillation, and acute coronary syndrome — with a big data architecture that required high-throughput proteomics across thousands of patients.
• LITMUS
  One of the largest NAFLD biomarker validation studies in Europe, running seven years to 2024, positioning SomaLogic at the center of the emerging non-invasive liver diagnostics market.